MetrionAIIntelligence

Sign in Register

Home Watchlist Market News High Impact News Market Movers Screener Portfolio Calculators Heatmap Compare Calendars Crypto Forex Macro Maps

Research Tools

Financial Analysis Analyst Estimates Insider Trading Market Guide Trading Ideas Charts

Financial Analysis

Highlights Income Statement Balance Sheet Cash Flow Multiples Profitability

Loading market dashboard

My Watchlist

Sign in to track securities

Create an account to keep a persistent watchlist.

Home High Impact News Market Movers

Back to markets

zacks.com/April 8, 2026 at 9:41 AMINSM

Insmed Ends Brinsupri Development in Skin Disease Post Study Failure

INSM scraps Brinsupri for HS after phase IIb failure, with placebo outperforming treatment despite no safety issues.

Open original source